15 Sets Of Cooling Sheets To Make Sleeping Hot A Thing Of The Past
So what did we look for when finding these 15 reviewer-loved sheet sets? 100% cotton and 100% linen reign supreme when it comes to cooling fabrics. Cotton is lightweight and breathable, and linen ups the ante by also being moisture-wicking. However, cotton is very durable (especially long- or extra-long staple cotton like Supima), while linen is less so.We also included a mix of sateen- and percale-weave sheets. Sateen sheets are super smooth, drape easily, and have a subtle sheen to them. Percale sheets have more of a crisp, cool feeling with a matte finish — think of a freshly laundered shirt! We'll also point out if the set is Oeko-Tex certified. This means it has been independently tested for harmful substances to ensure that it is suitable for humans to use — that's super important for something that makes contact with your skin on a nightly basis!We decided not to include bamboo sheets, as most of them undergo less sustainable production methods. Most sheets that advertise themselves as "bamboo" are actually made of bamboo-viscose (aka bamboo-rayon) or bamboo-lyocell, which are produced in ways that involve toxic chemicals that can become pollutants. You can read more about bamboo fabrics at The Council of Fashion Designers of America.Oh, and microfiber is not the best choice when it comes to staying cool. It's tightly-woven, meaning your body heat won't escape as easily.Okay, now let's find you a new sheet set!!!
A wildly popular 400-thread count cotton sateen cooling sheet set so soft and cooling, you'll never throw them off you in the middle of the night when you suddenly feel like someone cranked up the thermostat to 100 degrees. Bonus — reviewers say these hold up super well after repeated washings with very few wrinkles and no shrinkage!
A 100% European linen set that comes in a gingham pattern so country-chic it might just mentally transport you to a cozy cabin in the woods. Reviewers rave over them for their super lightweight feel. (Oh, and that there's an option without a flat sheet!)
A set made with 100% Egyptian cotton in a percale weave — which is perfect for curling up under on a 90+ degree day while watching Uptown Girls and singing along to 🎶na na na na na na na na, sheets of Egyptian cotton. 🎶 Oh, and Egyptian cotton is known for its durability, so these should last you for years to come.
A set of 100% organic cotton sheets that come packaged in a reusable fabric bag, which is so much better than the flimsy plastic other sets come in. Several reviewers say these are thin enough to feel comy for hot sleepers, yet sturdy enough to stand up to many washes — one reviewer says years worth!
A splurge-worthy set of Supima cotton sheets with a super smooth sateen weave that'll tell night sweats to take a hike. One reviewer even compared these to hotel sheets, which is truly the highest compliment you can give to a sheet set.
A set of 100% cotton sateen sheets that are BELOVED by Target reviewers. No, really, I think some of these reviewers are counting on these becoming a family heirloom. That's probably because of the smooth 400-thread count wrinkle-resistant fabric, and the extremely helpful "top or bottom" tags so you know which side is which. If you've ever almost given up on making your bed and just flopping on the couch because you lined the fitted sheet's corners up incorrectly, these are for you.
A pure linen set so buttery smooth you'll roll around on it like a dog going carpet swimming. It's designed to absorb moisture without feeling wet to the touch, so if night sweats come to pay you a visit, they'll be quickly whisked away with barely a trace.
A set made with 100% pima cotton (meaning they're luxuriously soft, silky, and long-lasting compared to regular cotton fibers) and a percale weave for a crisp, cool feel and matte finish. And can we talk about the floral prints?! Absolutely stunning for any time of the year = worth the investment.
A set of brightly printed cotton bedsheets so you can add a vibrant summer vibe to your bed while you escape from the grueling summer temps. These get rave reviews for the bold prints that actually look as nice in person as they do in the product photos, and for having a ~crisp~ percale texture that'll give you that *fresh sheet* feeling every night.
A super sweet rainbow set — it's made with 100% cotton, meaning it'll be light and breathable enough to keep kids (or your inner child) comfy and cool all afternoon long, when it's time for a nap, *and* all night long.
A set of cotton sheets that'll combine your love for bold, vibrant patterns and breathable fabrics, thanks to the percale weave. The fitted sheet can easily fit mattresses up to 18 inches deep, so they might just make you dread sheet-changing-day a little less.
Or a cotton set featuring a super vibrant red floral pattern so you can make it look like spring every single day of the year. The breathable percale weave will also make it feel like spring too — not too cold, not too hot.
Or! A 100% cotton set made with a smooth sateen weave that'll drape super elegantly over your bed and basically turn it into a work of art. Reviewers say they hold up for years, and some have even picked up extra sets!
A chic set made with 100% stone-washed linen — come for the lightweight softness, stay for the dramatic flair of the ruffled pillowcases.
An absolutely adorable set made with 100% cotton and a percale weave — the coffee that's printed on them might be hot, but you'll stay as cool as a glass of cold brew. No judgment if they inspire you to have breakfast-in-bed and leave croissant crumbs all over them. It'll just elevate the vibe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Researchers hope the findings will boost 'validity and credibility' for patients
People diagnosed with ME/chronic fatigue syndrome (CFS) have significant differences in their DNA compared to those without the condition, according to a 'groundbreaking' new study. Scientists said the findings offer the first robust evidence that genes contribute to a person's chance of developing the disease. The DecodeME study, said to be the largest of its kind in the world, uncovered eight areas of genetic code in people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) that are markedly different to the DNA of people without the condition. Researchers hope the findings will boost 'validity and credibility' for patients, and help rebuff some of the stigma and lack of belief that exists around the condition. There is currently no diagnostic test or cure for ME/CFS, which is believed to affect around 67 million people worldwide, and very little is known about what causes it. A key feature of the condition is a disproportionate worsening of symptoms following even minor physical or mental activity, which is known as post-exertional malaise (PEM,) while other symptoms include pain, brain fog and extreme energy limitations that do not improve with rest. For the new study, researchers analysed 15,579 DNA samples from the 27,000 people with ME/CFS participating in DecodeME, described as the world's largest data set of people with the disease. The eight regions of DNA where scientists found genetic differences involve genes linked to the immune and nervous systems. At least two of the genetic signals relate to how the body responds to infection, which researchers said aligns with long-standing patient reports that the onset of symptoms often followed an infectious illness. Professor Chris Ponting, DecodeME investigator from the University of Edinburgh, said: 'This is a wake-up call. These extraordinary DNA results speak the language of ME/CFS, often recounting people's ME/CFS symptoms. 'DecodeME's eight genetic signals reveal much about why infection triggers ME/CFS and why pain is a common symptom. 'ME/CFS is a serious illness and we now know that someone's genetics can tip the balance on whether they are diagnosed with it.' As a person's DNA does not change over time, experts say the genetic signals identified would not have developed because of ME/CFS and are therefore likely to reflect the causes of the disease. Populations used in the initial study were limited to those from European ancestries. READ MORE: We must protect chronic pain management services: it's not just about 'old people' I suffer from chronic fatigue syndrome. I know it's real - so why don't doctors? The sorry tale of Scotland's chronic pain crisis DecodeME research studying DNA data from all ancestries is ongoing. ME/CFS, thought to affect around 404,000 people in the UK, affects more females than males, although researchers found nothing to explain why this is the case. The DecodeME team is now calling on researchers from around the world to access its 'rich' dataset and help drive forward targeted studies into ME/CFS. Sonya Chowdhury, chief executive of Action for ME and a DecodeME co-investigator, said: 'These results are groundbreaking. 'With DecodeME, we have gone from knowing next to nothing about the causes of ME/CFS, to giving researchers clear targets.' She also hopes the discoveries will help change the way the condition is viewed. Ms Chowdhury said: 'This really adds validity and credibility for people with ME. 'We know that many people have experienced comments like ME is not real, or they've been to doctors and been disbelieved or told that it's not a real illness. 'Whilst things have changed and continue to change, that is still the case for some people and we hear that repeatedly as a charity. 'Being able to take this study into the treatment room and say there are genetic causes that play a part in ME is going to be really significant for individuals. 'It will rebuff that lack of belief and the stigma that exists.' The findings have been reported in a pre-print publication, or unpublished study. During a media briefing about the study, researchers were asked about similarities between the symptoms of long Covid and ME/CFS. Prof Ponting said: 'It's very clear that the symptomology between long Covid and ME is highly similar. 'Not for everyone but there are substantial similarities but as a geneticist the key question for me is are there overlapping genetic factors, and we haven't found that in DECode ME with the methods that we've employed. 'One of the key things that we're doing is enabling others to use their different approaches to ask and answer the same question.' DecodeME is a collaboration between the University of Edinburgh, the charity Action for ME, the Forward ME alliance of charities, and people with ME/CFS. It is funded by the Medical Research Council and National Institute for Health and Care Research.
Business Wire
11 hours ago
- Business Wire
Northwell's Staten Island University Hospital Performs First U.S. Procedure With New BioHealx Device for Complex Anal Fistulas
STATEN ISLAND, N.Y.--(BUSINESS WIRE)--Northwell's Staten Island University Hospital (SIUH) is the first medical center in the United States to perform surgery using the newly FDA-cleared BioHealx ®Anal Fistula Device - offering new hope to patients suffering from complex and often debilitating anal fistulas. The procedures were performed by colorectal surgeons Poppy Addison, MD, and Giovanni Bonomo, MD, director of colorectal surgery. The BioHealx device, developed by Irish-based Signum Surgical, represents a significant advancement in the treatment of complex anal fistulas, notoriously difficult to treat with current surgical options. The minimally invasive, absorbable implant is designed to close fistula tract as it traverses the anal sphincter complex, without involving any significant disruption of the anorectal anatomy. Early European data demonstrated an 84% success rate, far exceeding traditional approaches that often have success rates closer to 60% and are associated with the need for multiple procedures to finally achieve healing. 'Historically, these surgeries have been long, complex, traumatic to the anorectum and carried the risk of recurrence and incontinence,' said Dr. Bonomo. 'The BioHealx device is intuitive, efficient, and minimizes surgical trauma. If we can replicate the European outcomes, this could set a new standard of care in fistula treatment.' Approximately, 90,000 complex anal fistula procedures are performed yearly. These fistulas predominantly affect men between ages 18 and 50, and disrupts their quality of life due to anal pain, foul-smelling drainage, and recurrent infection. Fistulas can recur even after what appears to be healing at the skin level due to persistence of the transsphincteric fistula tract, and many patients undergo multiple interventions before finding relief. 'Rectal fistulas are under-researched and have lacked a reliable, standardized solution,' said Dr. Addison. 'This device has the potential to optimize care, shorten recovery, and reduce recurrence, all while preserving continence, which is a critical concern for our patients.' Before surgery, a seton drain is placed to help mature the fistula tract and to provide for clear identification of the internal fistula opening. During the BioHealx procedure, the seton is removed, the tract is brushed clean, and a small flap is created to expose the internal sphincter at the location of internal opening. The corkscrew-shaped BioHealx implant is then inserted to compress the tissue around the fistula tract as it traverses the width of the sphincter complex to deliver primary healing by direct tissue apposition. The flap is closed over the internal opening and internal anal sphincter, while the outer tract is partially opened for optimal drainage - all without damaging the sphincter muscle nor disrupting the anal canal. The implant itself is made from bioabsorbable polylactic glycolic acid and naturally dissolves in the body within six to twelve months, leaving no permanent material behind. The inspiration for the BioHealx device dates back to 2013 when engineers Eoin Bambury and Moshe Zilversmit, co-founders of Signum Surgical, met during a government-sponsored fellowship in Ireland. After observing the repeated failure of traditional surgeries to treat anal fistulas, often requiring four or more operations, they launched Signum Surgical in 2016 to develop a better solution. 'The key was identifying the failure of primary healing of the transsphincteric portion of the fistula tract as the root cause of surgical failure,' said Bambury. 'Our goal was to close it effectively without damaging the anal canal nor the anal sphincter. After years of research, clinical trials, and design refinement, we're proud to see our work helping patients here in the U.S.' SIUH's successful completion of the first U.S. procedures using the BioHealx device represents a critical milestone in the adoption of innovative, patient-centered technology across Northwell Health. 'Northwell has always championed advanced technologies that improve outcomes and quality of life,' said Dr. Bonomo. 'This is the kind of breakthrough that can change how we treat complex anal fistulas nationwide.' Drs. Bonomo and Addison will continue evaluating patient outcomes to help guide future adoption and research of the BioHealx procedure. With a shorter learning curve than many other surgical techniques, the team believes the procedure can be easily adopted across the entire system. 'We're incredibly optimistic,' said Dr. Addison. 'This device doesn't burn any bridges - it's safe, effective, and easy to use. If it doesn't work, patients still have all their future options with essentially normal anorectal anatomy. But if it does, it can spare them years of painful, frustrating treatments.'
Yahoo
14 hours ago
- Yahoo
MedTech Europe renews call for zero-tariff deal as Trump imposes 15% levy on EU
MedTech Europe has reiterated the importance of tariff-free trade for medical technologies following the US decision to impose reciprocal tariffs of 15% on the majority of goods from Europe. The White House's confirmation of the latest rate, which President Trump previously threatened could be set at 30% if an agreement was not reached by 1 August, follows an agreement made during critical talks between Trump and European Commission (EC) President Ursula von der Leyen during the US President's recent visit to his Scottish golf courses. A White House communique from 31 July claimed the imposition of the 15% tariff rate was necessary due to a 'large and persistent' annual US goods trade deficit that constituted an 'unusual and extraordinary threat' to the country's national security and economy. Under the current deal, zero tariffs have been confirmed for goods such as natural resources, critical raw materials, all aircraft and components, and semiconductor equipment. While there has been no specific word on medical technologies, EU officials expect the list of goods subject to zero rates to be expanded within the coming weeks. MedTech Europe welcomed the progress made in the recent agreement to avert the 'worst-case scenario' but stated it remained 'deeply concerned' that the 15% tariff rate may apply to certain European medical technology exports to the US. According to MedTech Europe, ensuring tariff-free transatlantic trade for medical technologies is paramount, for patients, the provision of healthcare on both sides of the Atlantic, leadership in health innovation, and to ensure competitiveness in the global economy. MedTech Europe CEO Oliver Bisazza said: 'Patients must not bear the cost of trade tensions. Medical technologies are fundamental to delivering care and saving lives. 'Leaving them burdened by tariffs undermines healthcare systems, slows innovation, and ultimately impacts patients. We need to go further. The zero-for-zero solution is urgent.' MedTech Europe is currently assessing the implications of the EU-US agreement for the medical device sector and said it awaits further details. In its concluding remarks, the trade body said: 'MedTech Europe calls on policymakers to maintain momentum in negotiations and develop a dedicated bilateral solution that fully eliminates tariffs on medical technologies and their essential components.' Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence "MedTech Europe renews call for zero-tariff deal as Trump imposes 15% levy on EU" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
